Rising prevalence of conjunctivitis is propelling the growth of the viral conjunctivitis drugs market

 

Viral Conjunctivitis Drugs Market

The most commonly used viral conjunctivitis drugs are antibiotics. These drugs, including amikacin, doxycycline, and gentamycin are effective in the treatment of this condition.  Doxycycline can cause nausea, vomiting, diarrhea, dizziness, hives, and even bleeding, and these effects can be severe if they persist for a long time. Gentamycin, on the other hand, causes diarrhea and produces thin discharge from the nose.

The growing prevalence of conjunctivitis or pink eye is a key factor fueling the growth of the viral conjunctivitis drugs market. Conjunctivitis drugs are used to treat inflammation or swelling of the conjunctiva. A rise in hygiene and awareness coupled with the increasing healthcare expenditure is also propelling the growth of viral conjunctivitis drugs. According to the World Health Organization, global spending on health continues to rise. It was US$ 7.8 trillion in 2017 or about 10% of GDP and $1,080 per capita – up from US$ 7.6 trillion in 2016. The increasing geriatric population which is increasing the prevalence rate of this infection is further anticipated to augment the growth of the viral conjunctivitis drugs market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of viral conjunctivitis in the region. According to the National Center for Biotechnology Information, it is estimated that acute conjunctivitis affects 6 million people annually in the United States.2 The cost of treating bacterial conjunctivitis alone was estimated to be $377 million to $857 million per year.

Key Developments:

1.      In July 2017, Lupin Ltd has launched in the US market its generic version of Moxifloxacin Hydrochloride Ophthalmic solution used for treating bacterial conjunctivitis.

2.      In December 2020, Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye announced the submission of the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use

3.      In March 2020, Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.

4.      In March 2019, Alembic Pharmaceuticals announced that it has received approval from the United States Food and Drug Administration for sales of a generic version of Mylan’s Optivar eye-drops


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region